Drugs / Fontolizumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00281294 | Dec 2005 → Dec 2006 | rheumatoid arthritis | PDL BioPharma, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00072943 | Mar 2002 → Apr 2004 | Crohn disease, colitis | Facet Biotech | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fontolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00281294 ↗ |
| Known as | HuZAF | “A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease” NCT00072943 ↗ |
| Action | Inhibit | “binds and blocks IFN-γ, a protein in the immune system” NCT00072943 ↗ |
| Modality | Monoclonal antibody | “HuZAF is a humanized anti-Interferon-gamma (anti-IFN-γ) monoclonal antibody” NCT00072943 ↗ |
| Route | Intravenous | “The initial dose of study drug will be given intravenously, injected into a vein in the arm.” NCT00072943 ↗ |
| Target | IFNG | “binds and blocks IFN-γ, a protein in the immune system” NCT00072943 ↗ |